Merit

For research use only. Not for human consumption. Not medical advice — consult a licensed clinician.

Growth Hormone Secretagogues

Hexarelin

Also known as: Examorelin

Hexarelin (His-D-2MeTrp-Ala-Trp-D-Phe-Lys-NH2) is a synthetic hexapeptide growth hormone secretagogue developed by Mediolanum (Italy) in the 1990s. It is a potent ghrelin-receptor (GHSR-1a) agonist that also binds the CD36 scavenger receptor, giving it a cardioprotective signal distinct from other GHRPs. It is not FDA-approved for any indication and remains a research-only compound; its clinical development for GH deficiency and cardiac indications did not reach approval. A defining feature versus other GHRPs is rapid, pronounced tachyphylaxis with chronic daily dosing.

Real-time market data

Pricing for Hexarelin

Live vendor pricing, normalized to $/mg so sizes compare fairly — fused with each seller's Merit trust score and latest independent COA purity. Prices refresh daily.

Average price

$11.15/mg

range $6.50–$18.40/mg

Sellers

22

from $0.00

45-day trend

-7.1%

vs 45-day avg $/mg

18 of 22 sellers have a current price· 12 stale listings hidden (not seen in 7 days)

Prices observed from public storefronts (last 24h), normalized to $/mg. "Evidence" is Merit's 0–100 Merit Score, derived only from observable verification evidence (methodology on /about); "Purity" is the latest independent COA. Some buy links are affiliate links — Merit may earn a commission at no extra cost to you, and where a vendor offers one, the code shown gets you a discount at their checkout. Affiliate status never affects price data, ranking, or the Merit Score (full policy on /disclosure). Research use only.

Independent evidence

COAs for Hexarelin

13 third-party tests across 4 vendors. Each card links to the full report.

All 13 COAs for Hexarelin →
Measured purity 99.2%–99.7% across 7 COAs
Measured purity over time
Aggregated · 3rd-party listing
99.19 %
May 2026
Horizon Analytical

For

Hexarelin

by Pepsgpt· batch P-7132129-P

Aggregated · 3rd-party listing
99.37 %
Mar 2026
Freedom Diagnostics Moderate

For

Hexarelin

by Real Peptides

✓ Vendor-published
99.55 %
Jan 2026
Janoshik Analytical Limited

For

Hexarelin

by Ruo Bio

COA on file
Aggregated · 3rd-party listing
99.71 %
Jan 2026
Freedom Diagnostics Moderate · HPLC

For

Hexarelin

by MedGe Peptides· batch HEX5LT12

Aggregated · 3rd-party listing
99.71 %
Jan 2026
Freedom Diagnostics Moderate · HPLC

For

Hexarelin

by MedGe Peptides· batch HEXSLT12

Aggregated · 3rd-party listing
99.48 %
Sep 2025
Janoshik Analytical Limited · HPLC

For

Hexarelin

by Skye Peptides· batch HEX25-5-001

Aggregated · 3rd-party listing
99.27 %
Aug 2024
Janoshik Analytical Limited · HPLC

For

Hexarelin

by Peptide Tech· batch 102-HN

Aggregated · 3rd-party listing
99.24 %
Vanguard Laboratory Strong

For

Hexarelin

by Kimera Chems· batch Blue Cap

Aggregated · 3rd-party listing
99.04 %
Vanguard Laboratory Strong

For

Hexarelin

by Moglabs· batch HEX002

Aggregated · 3rd-party listing
—
May 2026

Purity not on file

Horizon Analytical

For

Hexarelin

by Pepsgpt· batch P-7132129-E

Aggregated · 3rd-party listing
—
Mar 2026

Purity not on file

Freedom Diagnostics Moderate

For

Hexarelin

by Real Peptides

Aggregated · 3rd-party listing
—
Sep 2025

Purity not on file

Janoshik Analytical Limited

For

Hexarelin

by Skye Peptides· batch HEX25-5-001

✓ Vendor-published
—

Purity not on file

Lab unknown

For

Hexarelin

by Ruo Bio

COA on file
Research depth

12 citations indexed for Hexarelin

All research on Hexarelin →

animal · 2026

Hexarelin promotes the survival of retinal ganglion cells after optic nerve transection

Objective Hexarelin is a growth hormone secretagogue receptor type 1a agonist with a potent anti-apoptotic effect. We studied the neuroprotective effect of hexarelin on the survival of retinal ganglion cells (RGCs) in the retina following optic nerve transection (ONT).

review · 2026

The emerging landscape of performance-enhancing peptides modulating GH-IGF1 axis: bridging the gap between clinical evidence and patient self-administration

Performance-enhancing drugs (PEDs) marketed as "research compounds" include unregulated peptides intended to modulate the growth hormone-insulin-like growth factor-1 (GH-IGF-1) axis.

review · 2026

Therapeutic Peptides in Aesthetic, Metabolic and Endocrine Conditions: Effects, Safety, Clinical Applications, and Future Perspectives

Therapeutic peptides are short chains of amino acids used to treat metabolic and endocrine conditions such as obesity and type 2 diabetes.

Study · 2025

Identification of alexamorelin consumption biomarkers using human hepatocyte incubations and high-resolution mass spectrometry

Alexamorelin is a synthetic peptide and growth hormone secretagogue (GHS) with potential performance-enhancing properties, making its use and abuse a topic of interest in clinical research and doping monitoring.

review · 2025

Cisplatin-Induced Muscle Wasting and Atrophy: Molecular Mechanism and Potential Therapeutic Interventions

Platinum-based chemotherapeutics, particularly cisplatin, are crucial in the treatment of various malignancies due to their strong antitumor effects. However, a significant side effect of cisplatin is muscle atrophy, which severely impairs physical strength, diminishes quality of life and complicates cancer therapy.

Study · 2024

Pharmacological targeting of the hyper-inflammatory response to SARS-CoV-2-infected K18-hACE2 mice using a cluster of differentiation 36 receptor modulator

The scientific and medical community faced an unprecedented global health hazard that led to nearly 7 million deaths attributable to the rapid spread of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection.